Surrozen, Inc./DE Payments for Repurchase of Warrants
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Surrozen, Inc./DE payments for repurchase of warrants for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Surrozen, Inc./DE payments for repurchase of warrants for fiscal 2022 was $85.00K.
- Surrozen, Inc./DE payments for repurchase of warrants for fiscal 2021 was $0.00.
| Period end | Payments for Repurchase of Warrants 3 month | Payments for Repurchase of Warrants 12 month |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-04-10 | |
| 2022-12-31 | $85.00K 10-K · filed 2024-04-10 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |